According to a recent LinkedIn post from Touchlight, new data suggest that its dbDNA platform, when used with the FuGENE 4K transfection reagent, may substantially increase lentiviral vector production versus traditional plasmid DNA. The post cites a comparative study in 3rd‑generation LVV systems in HEK293T cells, indicating up to threefold higher infectious titers in adherent cultures.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content also highlights twofold greater infectious titers while using 50% less total DNA and transfection reagent, which is presented as supportive of improved cost of goods. In addition, the post notes reported gains of 2.4× higher titers in a scalable, suspension LVV production process and directs readers to an application note for further data.
For investors, the post suggests potential process and cost advantages in lentiviral vector manufacturing that could enhance Touchlight’s value proposition in gene and cell therapy supply chains. If these performance and efficiency gains are validated at scale and adopted by CDMOs or biopharma partners, they could strengthen the company’s competitive position in nucleic acid manufacturing and support future commercial traction.